Paid Clinical Trials in Chattanooga, TN

As of June 2026, 144 paid clinical trials are recruiting in Chattanooga, Tennessee. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.

Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

144 clinical trials

↓ Download CSV

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

for Chronic Lymphocytic Leukemia

Drug: Sonrotoclax

34 locations incl. Laguna Hills

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT06943872·Phase 3·Recruiting

Apply to this trial

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

for Agitation

53 locations incl. Homewood

Sponsor: Celgene

Sex: All·Age: 55 - 90

Code: NCT06808984·Phase 2·Recruiting

Apply to this trial

ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

for Autosomal Dominant Polycystic Kidney Disease

35 locations incl. Garden Grove

Sponsor: Calico Life Sciences LLC

Sex: All·Age: 18 - 55

Code: NCT06902558·Phase 2·Recruiting

Apply to this trial

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

for Cardiovascular Disease

315 locations incl. Athens

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT07000357·Phase 3·Recruiting

Apply to this trial

CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)

for Type 1 Diabetes Mellitus

30 locations incl. Tucson

Sponsor: COUR Pharmaceutical Development Company, Inc.

Sex: All·Age: 12 - 35

Code: NCT06783309·Phase 1, Phase 2·Recruiting

Apply to this trial

Pivotal Study of Voro Urologic Scaffold

for Radical Prostatectomy

19 locations incl. Phoenix

Sponsor: Levee Medical, Inc.

Sex: Male·Age: 45+

Code: NCT06873581·Phase 3·Recruiting

Apply to this trial

A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

for New Onset Generalized Myasthenia Gravis (gMG)

Drug: Efgartigimod PH20 SC

18 locations incl. La Jolla

Sponsor: argenx

Sex: All·Age: 18+

Code: NCT06909214·Phase 4·Recruiting

Apply to this trial

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

for Stage I Mixed Cell Type Kidney Wilms Tumor

146 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 30

Code: NCT06401330·Phase 3·Recruiting

Apply to this trial

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

85 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06890598·Phase 3·Recruiting

Apply to this trial

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

for Lung Cancer - Non Small Cell Squamous

Drug: Petosemtamab

6 locations incl. St. Petersburg

Sponsor: Merus B.V.

Sex: All·Age: 18+

Code: NCT07353957·Phase 2·Recruiting

Apply to this trial

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

for B-Cell Non-Hodgkins Lymphoma

Drug: Glofitamab

33 locations incl. Anchorage

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06806033·Phase 2·Recruiting

Apply to this trial

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

for APOL1-Mediated Kidney Disease

67 locations incl. Alabaster

Sponsor: AstraZeneca

Sex: All·Age: 18 - 65

Code: NCT06824987·Phase 2·Recruiting

Apply to this trial

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

for Chronic Kidney Disease and Hypertension

Drug: Dapagliflozin

132 locations incl. Fairhope

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06742723·Phase 3·Recruiting

Apply to this trial

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

for Proteinuric Kidney Disease

Drug: MZE829

72 locations incl. Decatur

Sponsor: Maze Therapeutics

Sex: All·Age: 18 - 68

Code: NCT06830629·Phase 2·Recruiting

Apply to this trial

Non-Invasive Preeclampsia Screening and Biobank

for Preeclampsia (PE)

21 locations incl. Glendale

Sponsor: Sequenom, Inc.

Sex: Female·Age: 18+·Accepts healthy volunteers

Code: NCT06643741·Recruiting

Apply to this trial

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

for Graves' Disease

Drug: IMVT-1402

64 locations incl. Phoenix

Sponsor: Immunovant Sciences GmbH

Sex: All·Age: 18 - 75

Code: NCT06727604·Phase 2·Recruiting

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

Drug: Amivantamab

150 locations incl. Daphne

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting

Apply to this trial

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

for Colorectal Neoplasms

Drug: Amivantamab

70 locations incl. Chandler

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06750094·Phase 3·Recruiting

Apply to this trial

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

for COVID-19 SARS-CoV-2 Infection

84 locations incl. Little Rock

Sponsor: Pfizer

Sex: All·Age: 12+

Code: NCT06679140·Phase 3·Recruiting

Apply to this trial

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

for Patients With Non-Small Cell Lung Cancer

79 locations incl. Beverly Hills

Sponsor: OSE Immunotherapeutics

Sex: All·Age: 18+

Code: NCT06472245·Phase 3·Recruiting

Apply to this trial

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

for Non-squamous Non-small Cell Lung Cancer

Drug: Rilvegostomig

77 locations incl. Mobile

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06627647·Phase 3·Recruiting

Apply to this trial

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

Drug: Rilvegostomig

74 locations incl. Tucson

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06692738·Phase 3·Recruiting

Apply to this trial

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

for Metabolic Dysfunction Associated Steatohepatitis

Drug: Survodutide

125 locations incl. Peoria

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06632457·Phase 3·Recruiting

Apply to this trial

FastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW

for Chronic Total Occlusion of Artery of the Extremities

6 locations incl. Wilmington

Sponsor: Versono Medical Ltd

Sex: All·Age: 18 - 85

Code: NCT06492733·Recruiting

Apply to this trial

Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants

for Breast Reconstruction

22 locations incl. Los Angeles

Sponsor: AbbVie

Sex: Female·Age: 18+

Code: NCT06575192·Phase 3·Recruiting

Apply to this trial

The THOR IDE Study

for Peripheral Artery Disease

29 locations incl. St. Helena

Sponsor: Philips Clinical & Medical Affairs Global

Sex: All·Age: 18+

Code: NCT05916950·Recruiting

Apply to this trial

Open-Label Extension Study of Setmelanotide

for Obesity Associated With Defects in Leptin-melanocortin Pathway

13 locations incl. Scottsdale

Sponsor: Rhythm Pharmaceuticals, Inc.

Sex: All·Age: 2+

Code: NCT06596135·Phase 3·Enrolling By Invitation

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

for Metastatic Non-small Cell Lung Cancer

Drug: Osimertinib

34 locations incl. Fayetteville

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT06417814·Phase 3·Recruiting

Apply to this trial

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

for Head and Neck Squamous Cell Carcinoma

Drug: Petosemtamab

37 locations incl. Mobile

Sponsor: Merus B.V.

Sex: All·Age: 18+

Code: NCT06525220·Phase 3·Recruiting

Apply to this trial

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

for Metabolic Dysfunction Associated Steatohepatitis (MASH)

Drug: Survodutide

165 locations incl. Birmingham

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06632444·Phase 3·Recruiting

Apply to this trial

Study to Evaluate the Diagnostic Performance of of MAGENTIQ-COLO During Colonoscopy.

for Screening Colonoscopy

2 locations incl. Baltimore

Sponsor: Magentiq Eye LTD

Sex: All·Age: 45 - 80·Accepts healthy volunteers

Code: NCT06568523·Not Yet Recruiting

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

for Migraine

Drug: Ubrogepant

103 locations incl. Birmingham

Sponsor: AbbVie

Sex: Female·Age: 18+

Code: NCT06417775·Phase 3·Recruiting

Apply to this trial

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

for Melanoma

104 locations incl. Chandler

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06246916·Phase 3·Recruiting

Apply to this trial

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

for Advanced Breast Cancer

Drug: Camizestrant

54 locations incl. Gilbert

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06380751·Phase 3·Recruiting

Apply to this trial

Long-term Safety and Tolerability of BHV-7000

for Focal Epilepsy

115 locations incl. Birmingham

Sponsor: Biohaven Therapeutics Ltd.

Sex: All·Age: 18 - 75

Code: NCT06443463·Phase 2·Enrolling By Invitation

Continuation Protocol for Obstructive Sleep Apnea (OSA)

for OSA

93 locations incl. Birmingham

Sponsor: Apnimed

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT06566820·Phase 3·Enrolling By Invitation

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

for Cardiovascular Risk

Drug: Ziltivekimab

208 locations incl. Alexander City

Sponsor: Novo Nordisk A/S

Sex: All·Age: 18+

Code: NCT06118281·Phase 3·Recruiting

Apply to this trial

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

for Generalized Myasthenia Gravis

21 locations incl. Phoenix

Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Sex: All·Age: 18+

Code: NCT06463587·Phase 3·Recruiting

Apply to this trial

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

for Head and Neck Squamous Cell Carcinoma

Drug: Petosemtamab

61 locations incl. Mobile

Sponsor: Merus B.V.

Sex: All·Age: 18+

Code: NCT06496178·Phase 3·Recruiting

Apply to this trial

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

for Myelofibrosis

Drug: Ruxolitinib

58 locations incl. Birmingham

Sponsor: Kartos Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06479135·Phase 3·Recruiting

Apply to this trial